Efficacy of brilliant blue G in Descemet Membrane Endothelial Keratoplasty

Efficacy of brilliant blue G in Descemet Membrane Endothelial Keratoplasty - Efficacy of BBG in DMEK

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026311

Enrollment

Registered

2017-03-01

Start date

2014-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bullous keratopathy

Interventions

The DMEK graft was stained with 0.1% BBG for5 minute and stored in oxyglutathione-containing intraocular irrigation solution until insertion 30 min later.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with corneal endothelial disease which preoperative visual acuity range from hand motion to 24/20. Iatrogenic bullous keratopathy; after argon laser iridotomy (ALI) , cataract surgery, vitrectomy, or glaucome filtrating surgery. Fuchs corneal endothelial dystrophy. Corneal endotheliopathy caused by pseudoexfoliation syndrome (PEX). Corneal endothelitis. Birth injury.

Exclusion criteria

Exclusion criteria: Cases in which the patient discontinued consultation during the 6 months of the postoperative follow-up period will be excluded.

Design outcomes

Primary

Measure	Time frame
Endothelial cell density (ECD): before, 3 months after, 6 months, 1 year after surgery.	—

Secondary

Measure	Time frame
The best spectacle-corrected visual acuity (BSCVA), and central corneal thickness (CCT): before, 3 months after, 6 months, 1 year after surgery.	—

Countries

Japan

Contacts

Public ContactTakahiko Hayashi

Yokohama Minami Kyosai Hospital Department of Ophthalmology

htakahiko-aikou@umin.ac.jp+81-45-787-2101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026